In a significant development for public health, NanoViricides Inc. (NYSE American: NNVC) has highlighted its drug candidate NV-387 as a potential treatment for the increasing measles outbreaks across the United States, Canada, the UK, and the European Union. With measles cases reaching alarming levels, the need for an effective treatment has never been more critical. The U.S. has reported 1,319 cases in 2025, surpassing the previous record set in 2019, while Canada has seen over 3,800 cases. The World Health Organization (WHO) reported 127,350 cases in Europe in 2024, the highest since 1997.
NV-387 has demonstrated effectiveness and safety in animal studies using humanized h-CD150+ knock-in mice and has successfully completed a Phase I clinical trial with no adverse events, indicating strong tolerability in humans. This positions NV-387 as a promising candidate to address the current gap in measles treatment, especially in light of vaccination challenges due to hesitancy and immune dysfunction. NanoViricides believes NV-387 may qualify for Orphan Drug and Fast Track designations, which could expedite its approval process and grant seven years of market exclusivity.
The potential of NV-387 to meet this urgent medical need is underscored by the absence of any approved drug specifically for measles. The company's announcement comes at a time when the global community is grappling with the resurgence of measles, a disease once considered near elimination in many parts of the world. For more information on NanoViricides' groundbreaking work, visit https://www.NanoViricides.com.
This development is not just a milestone for NanoViricides but also a beacon of hope for millions at risk of measles worldwide. The implications of NV-387's success extend beyond immediate treatment, potentially setting a precedent for the development of nanomedicine-based solutions for other viral infections. As the company moves towards Phase II clinical trials, the global health community watches closely, anticipating the impact of NV-387 on the ongoing measles crisis.
